HODGKIN LYMPHOMA AND T-CELL LYMPHOMA
How I treat high-risk Hodgkin lymphoma in first line
S.M. Ansell
Pathobiology of nodal peripheral T-cell lymphoma
S.A. Pileri
How I treat high-risk T-cell lymphomas
W.S. Kim
MANTLE CELL LYMPHOMA
Biological identification of high-risk mantle cell lymphoma
E. Campo
How I treat high-risk mantle cell lymphoma in first line
G. Hess
How I treat relapsed/refractory mantle cell lymphoma and new perspectives with CAR-T therapy
C. Visco
LARGE B-CELL LYMPHOMA
How I treat high-risk LBCL in first line
G. Nowakowski
Novel immunotherapies in relapsed/refractory DLBCL
C. Carlo-Stella
LECTURE I
Emerging immunotherapy in B-cell lymphomas: the role of bispecific antibodies
C.Thieblemont
INDOLENT LYMPHOMA
Biological of high-risk follicular lymphoma
C. Pott
How I treat high-risk follicular lymphoma
S. Ferrero
How I treat high-risk relapsed/refractory follicular lymphoma
A. Lopez-Guillermo
How I identify and treat high-risk marginal zone lymphoma
L. Arcaini
LECTURE II
Potential opportunities to overcome resistance to CAR-T therapy in diffuse large B-cell lymphoma
S.J. Schuster
CHRONIC LYMPHOCYTIC LEUKEMIA
How I treat high-risk relapsed/refractory CLL
T. Munir
MULTIPLE MYELOMA
Biology of high-risk multiple myeloma or the role of minimal residual disease in multiple myeloma
B. Paiva
How I treat young high-risk multiple myeloma patients
F. Gay
The challenging treatment of elderly multiple myeloma patients
T. Facon
ACUTE LYMPHOBLASTIC LEUKEMIA
Biology of high-risk ALL
S. Chiaretti
CAR-T in adult ALL
F. Lussana
LECTURE IV
Worldwide disparity of access to clinical trials and novel treatments in clinical practice
G. Gaidano
MYELODISPLASTIC SYNDROME
New approaches for treatment of MDS
A. Alfonso Piérola
Role of transplantation in high-risk MDS
G. Rivoli
ACUTE MYELOBLASTIC LEUKEMIA
Treatment of high-risk cytogenetic AML
P. Montesinos
Privacy Policy
|
Cookie Policy
×
